Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#3781 Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) – Data from the national registry SEPTRALU

Introduction: PRRT is established in the treatment repertoire for advanced neuroendocrine neoplasms (NEN) expressing somatostatin receptors, without strong evidence for other factors influencing their activity.

Conference:

Presenting Author:

Authors: Bello P, Mitjavila Casanovas M, Jimenez-Fonseca P, Cabezas Agrícola J, Hernando Cubero J,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, PRRT, prognosis, radionuclide therapy, survival,

#3779 177Lu-DOTATATE in advanced neuroendocrine neoplasms of different locations – Data from 552 cases in the SEPTRALU registry

Introduction: Peptide receptor radionuclide therapy (PRRT) is a therapeutic strategy selected via a marker, somatostatin receptor (SSTRs) expression, with activity in gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs). Its role in tumor sites outside the digestive tract remains unclear.

Conference:

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Bello P, de Matias Leralta J, Garcia Burillo A,

Keywords: 177Lu-DOTATATE, lung, neuroendocrine tumor, PRRT, pheochromocytoma, radionuclide therapy,

#3566 177-Lu-DOTATATE in 382 patients with somatostatin receptor–positive advanced tumors: Real-world data from the SEPTRALU registry

Introduction: NETTER-I and ERASMUS clinical trials have led to Lutetium177-DOTATATE (Lu177) approval in Spain.

Conference:

Presenting Author: Mitjavila M

Authors: Mitjavila Casanovas M, Pubul V, Belló P, García-Burillo A, Arbizu J,

Keywords: 177Lu-DOTATATE, SSTR-positive, efficacy, safety,

#3312 SEPTRALU registry of 177-Lu-DOTATATE in neuroendocrine tumors: Data from 321 patients in clinical practice

Introduction: Peptide receptor radionuclide therapy (PRRT) has a phase 3 clinical trial in advanced midgut neuroendocrine tumors (NETs) and clinical practice evidence in other locations.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Mitjavila Casanovas M, Bello P, Pubul V, Arbizu J, Gajate P,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, peptide receptor radionuclide therapy,

#2900 Radionuclide Therapy in the Continuum of Care of Neuroendocrine Tumors: Results of the SEPTRALU Study

Introduction: Peptide receptor radionuclide therapy (PRRT, Lu-177-DOTATATE) is safe and effective in neuroendocrine tumors (NET). However, the best sequence of administration is unknown.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Mitjavila Casanovas M, Carmona-Bayonas A, Pubul V, García-Cañamaque L, Aller J,

Keywords: Lu-177-DOTATATE, radionuclide, survival, treatment,